Show simple item record

dc.contributor.authorMoreau, Pen_US
dc.contributor.authorDimopoulos, MAen_US
dc.contributor.authorRichardson, PGen_US
dc.contributor.authorSiegel, DSen_US
dc.contributor.authorCavo, Men_US
dc.contributor.authorCorradini, Pen_US
dc.contributor.authorWeisel, Ken_US
dc.contributor.authorDelforge, Men_US
dc.contributor.authorO'Gorman, Pen_US
dc.contributor.authorSong, Ken_US
dc.contributor.authorChen, Cen_US
dc.contributor.authorBahlis, Nen_US
dc.contributor.authorOriol, Aen_US
dc.contributor.authorHansson, Men_US
dc.contributor.authorKaiser, Men_US
dc.contributor.authorAnttila, Pen_US
dc.contributor.authorRaymakers, Ren_US
dc.contributor.authorJoao, Cen_US
dc.contributor.authorCook, Gen_US
dc.contributor.authorSternas, Len_US
dc.contributor.authorBiyukov, Ten_US
dc.contributor.authorSlaughter, Aen_US
dc.contributor.authorHong, Ken_US
dc.contributor.authorHerring, Jen_US
dc.contributor.authorYu, Xen_US
dc.contributor.authorZaki, Men_US
dc.contributor.authorSan-Miguel, Jen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2018-02-19T09:57:15Z
dc.date.issued2017-09en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/28504846en_US
dc.identifier.citationEur J Haematol, 2017, 99 (3), pp. 199 - 206en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1246
dc.identifier.eissn1600-0609en_US
dc.identifier.doi10.1111/ejh.12903en_US
dc.description.abstractOBJECTIVES: Heavily pretreated patients with relapsed and refractory multiple myeloma are susceptible to treatment-related adverse events (AEs). Managing AEs are important to ensure patients continue therapy long enough to receive the best clinical benefit. Data from the MM-002, MM-003, and MM-010 trials were pooled to further characterize the safety profile of pomalidomide plus low-dose dexamethasone and AE management. METHODS: This analysis included 1088 patients who received ≥ 2 prior therapies, including lenalidomide and bortezomib, and progressed ≤ 60 days of last therapy. Patients received 28-day cycles of pomalidomide 4 mg/day on days 1-21 and low-dose dexamethasone 40 mg (20 mg if aged > 75 years) weekly until disease progression or unacceptable toxicity. Thromboprophylaxis was required. RESULTS: The most common grade 3/4 AEs were neutropenia (56.2%), anemia (32.3%), and thrombocytopenia (25.8%), which occurred within the first few cycles of treatment. Grade 3/4 infections occurred in 33.7% patients, of whom 13.9% had pneumonia, and 40.3% had neutropenia. Pomalidomide dose reductions or interruptions were reported in 24.2% and 66.0% of patients, respectively. AEs were managed by dose modifications and/or supportive care. CONCLUSIONS: Pomalidomide plus low-dose dexamethasone showed an acceptable safety profile, and AEs were well managed according to study protocols and established guidelines.en_US
dc.format.extent199 - 206en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectdexamethasoneen_US
dc.subjectpomalidomideen_US
dc.subjectpooled analysisen_US
dc.subjectrelapsed and refractory multiple myelomaen_US
dc.subjectsafetyen_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAged, 80 and overen_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectClinical Trials as Topicen_US
dc.subjectCombined Modality Therapyen_US
dc.subjectDexamethasoneen_US
dc.subjectDisease Managementen_US
dc.subjectDrug Resistance, Neoplasmen_US
dc.subjectDrug-Related Side Effects and Adverse Reactionsen_US
dc.subjectHumansen_US
dc.subjectMiddle Ageden_US
dc.subjectMulticenter Studies as Topicen_US
dc.subjectMultiple Myelomaen_US
dc.subjectNeoplasm Recurrence, Localen_US
dc.subjectThalidomideen_US
dc.subjectTime Factorsen_US
dc.titleAdverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.en_US
dc.typeJournal Article
dcterms.dateAccepted2015-05-09en_US
rioxxterms.versionofrecord10.1111/ejh.12903en_US
rioxxterms.licenseref.startdate2017-09en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfEur J Haematolen_US
pubs.issue3en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Myeloma Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume99en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMyeloma Groupen_US
dc.contributor.icrauthorKaiser, Martinen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record